Tearsheet

Sonoma Pharmaceuticals (SNOA)

Market Price (12/28/2025): $3.58 | Market Cap: $5.9 Mil
Sector: Health Care | Industry: Pharmaceuticals

Sonoma Pharmaceuticals (SNOA)

Market Price (12/28/2025): $3.58
Market Cap: $5.9 Mil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -42%	Weak multi-year price returns 2Y Excs Rtn is -29%, 3Y Excs Rtn is -166%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -3.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -18%
1	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, and Diabetes Management.		Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -14%
2			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -63%
3			High stock price volatility Vol 12M is 131%
4			Key risks SNOA key risks include [1] its current unprofitability and challenging need for additional capital given its small market cap and past shareholder dilution, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -42%
1	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, and Diabetes Management.
2	Weak multi-year price returns 2Y Excs Rtn is -29%, 3Y Excs Rtn is -166%
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -3.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -18%
4	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -14%
5	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -63%
6	High stock price volatility Vol 12M is 131%
7	Key risks SNOA key risks include [1] its current unprofitability and challenging need for additional capital given its small market cap and past shareholder dilution, Show more.

Valuation, Metrics & Events

	12/28/25	2024	2023	2022
Share Price CYE	$3.58	$2.69	$3.61	$22.40
Market Cap CYE ($ Mil)	5.9	3.9	2.0	3.5
Total Debt ($ Mil)	0.5	0.3	0.6	0.8
Total Cash ($ Mil)	3.0	5.4	3.1	3.8
Enterprise Value ($ Mil)	3.4	4.2	2.6	4.3
Valuation Ratios
P/S TTM	0.3	0.2	0.1	0.3
P/EBIT TTM	-1.9	-0.9	-0.3	-0.8
P/E TTM	-1.7	-1.0	-0.3	-0.7
P/FCF TTM	-2.5	-19.9	-0.7	-0.6
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9	4.5
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4	-1.3
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5

	12/28/25	2024	2023
Share Price CYE	$3.58	$2.69	$3.61
Market Cap CYE ($ Mil)	5.9	3.9	2.0
Total Debt ($ Mil)	0.5	0.3	0.6
Total Cash ($ Mil)	3.0	5.4	3.1
Enterprise Value ($ Mil)	3.4	4.2	2.6
Valuation Ratios
P/S TTM	0.3	0.2	0.1
P/EBIT TTM	-1.9	-0.9	-0.3
P/E TTM	-1.7	-1.0	-0.3
P/FCF TTM	-2.5	-19.9	-0.7
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	SNOA	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.0
Rev Chg Q	56.6%	7.3%
Rev Chg LTM	25.0%	6.1%
Rev Chg 3Y Avg	11.2%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-18.4%	18.8%
CFO/Rev LTM	-12.9%	20.4%
Net Inc Mgn	-20.5%	13.1%
VALUATION	VERY LOW
P/S	0.3	3.3
P/CFO	-2.7	15.8
P/FCF	-2.5	20.7
P/E	-1.7	23.7
STABILITY	VERY GOOD
Debt/Equity	0.09	0.21
Cash/Assets	0.22	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Countries Products are Sold In	over 55	11052025	Link
Number of Patients with Improved Outcomes	more than ten million	11062025	Link
Number of UK Stores for Acne Product Launch	over 1,200	8072025	Link

Upcoming
2/04/2026	Earnings Release	Rev: - EPS: -

SNOA Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Based on the available information for Sonoma Pharmaceuticals (SNOA) during the approximate time period from August 31, 2025, to December 28, 2025, the stock did not experience a decline of -18.9%. Instead, data indicates an overall positive performance for SNOA during 2025.

For instance, Sonoma Pharmaceuticals' stock price increased by 33.96% in 2025. Over the last 12 months leading up to December 25, 2025, the stock's price increased by 33.33%, with a year-to-date return of 35.32%. In the month preceding December 25, 2025, the stock also saw an increase of 11.31%.

News and financial reports released during and leading up to this period also highlighted positive developments:

1. Sonoma Pharmaceuticals reported strong financial results for its second fiscal quarter 2026 (ended September 30, 2025), including record quarterly revenue of $5.6 million, a 57% year-over-year increase, and improved net loss and EBITDA loss.

2. The company announced the launch of a new HOCl wound cleanser for Medline Industries, LP, on October 14, 2025, expanding its distribution into U.S. hospital systems.

3. Sonoma Pharmaceuticals expanded its market reach with FDA cosmetic product facility registration and Microcyn-based cosmetic product listing under MoCRA on October 7, 2025, allowing it to manufacture and commercialize Microcyn technology products as cosmetics in the U.S.

4. In June 2025, Sonoma Pharmaceuticals reported strong fiscal year and fourth quarter 2025 financial results, with revenues increasing 9% in Q4 2025 and 12% in FY 2025, along with improved net loss and EBITDA loss.

5. Sonoma successfully transitioned all of its commercialized products in Europe to the new European Union (EU) Medical Device Regulation (MDR) ahead of the 2028 deadline and registered its products with the MHRA in the United Kingdom in 2025.

Stock Movement Drivers

Fundamental Drivers

The -10.6% change in SNOA stock from 9/27/2025 to 12/27/2025 was primarily driven by a -21.1% change in the company's P/S Multiple.

	9272025	12272025	Change
Stock Price ($)	4.04	3.61	-10.64%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	14.91	16.94	13.58%
P/S Multiple	0.44	0.35	-21.09%
Shares Outstanding (Mil)	1.64	1.65	-0.30%
Cumulative Contribution			-10.64%

LTM = Last Twelve Months as of date shown

Market Drivers

9/27/2025 to 12/27/2025

	Return	Correlation
SNOA	-10.6%
Market (SPY)	4.3%	25.8%
Sector (XLV)	15.2%	-2.7%

Fundamental Drivers

The 25.8% change in SNOA stock from 6/28/2025 to 12/27/2025 was primarily driven by a 18.5% change in the company's Total Revenues ($ Mil).

	6282025	12272025	Change
Stock Price ($)	2.87	3.61	25.78%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	14.29	16.94	18.54%
P/S Multiple	0.32	0.35	8.28%
Shares Outstanding (Mil)	1.61	1.65	-2.05%
Cumulative Contribution			25.73%

LTM = Last Twelve Months as of date shown

Market Drivers

6/28/2025 to 12/27/2025

	Return	Correlation
SNOA	25.8%
Market (SPY)	12.6%	8.3%
Sector (XLV)	17.0%	7.8%

Fundamental Drivers

The 31.3% change in SNOA stock from 12/27/2024 to 12/27/2025 was primarily driven by a 67.1% change in the company's P/S Multiple.

	12272024	12272025	Change
Stock Price ($)	2.75	3.61	31.27%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	13.55	16.94	25.02%
P/S Multiple	0.21	0.35	67.14%
Shares Outstanding (Mil)	1.03	1.65	-59.19%
Cumulative Contribution			-14.71%

LTM = Last Twelve Months as of date shown

Market Drivers

12/27/2024 to 12/27/2025

	Return	Correlation
SNOA	31.3%
Market (SPY)	17.0%	17.5%
Sector (XLV)	13.8%	11.1%

Fundamental Drivers

The -82.1% change in SNOA stock from 12/28/2022 to 12/27/2025 was primarily driven by a -961.6% change in the company's Shares Outstanding (Mil).

	12282022	12272025	Change
Stock Price ($)	20.20	3.61	-82.13%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	12.51	16.94	35.34%
P/S Multiple	0.25	0.35	40.18%
Shares Outstanding (Mil)	0.16	1.65	-961.59%
Cumulative Contribution			-1734.62%

LTM = Last Twelve Months as of date shown

Market Drivers

12/28/2023 to 12/27/2025

	Return	Correlation
SNOA	-8.7%
Market (SPY)	48.0%	12.8%
Sector (XLV)	17.9%	9.9%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
SNOA Return	67%	-37%	-75%	-84%	-25%	35%	-96%
Peers Return	16%	38%	-12%	21%	26%	16%	150%
S&P 500 Return	16%	27%	-19%	24%	23%	18%	114%
Monthly Win Rates [3]
SNOA Win Rate	58%	25%	25%	50%	50%	42%
Peers Win Rate	52%	65%	42%	68%	57%	52%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
SNOA Max Drawdown	-15%	-40%	-78%	-87%	-30%	-30%
Peers Max Drawdown	-34%	-5%	-26%	-7%	-9%	-23%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)

How Low Can It Go

Unique Key	Event	SNOA	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-98.5%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	6756.3%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-37.4%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	59.9%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	Not Fully Recovered days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-94.5%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	1708.8%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	Not Fully Recovered days	120 days

Compare to HPQ, HPE, IBM, CSCO, AAPL

In The Past

Sonoma Pharmaceuticals's stock fell -98.5% during the 2022 Inflation Shock from a high on 2/16/2021. A -98.5% loss requires a 6756.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Sonoma Pharmaceuticals (SNOA)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; Lasercyn gel intended for the management of minor skin irritations; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Gramaderm for the treatment of topical mild to moderate acne; Microsafe, a surface disinfectant; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

AI Analysis | Feedback

Here are 1-2 brief analogies to describe Sonoma Pharmaceuticals (SNOA):

A specialized pharmaceutical company focusing on skin and wound care, similar to a focused version of Johnson & Johnson's medical or consumer health divisions.
A pharmaceutical company offering topical treatments and medical solutions, akin to a smaller, more specialized Bayer focused on dermatology and wound care.

AI Analysis | Feedback

Dermatology Products: Sonoma Pharmaceuticals offers a range of prescription and over-the-counter topical solutions and gels for various skin conditions like acne, eczema, and rosacea.
Wound Care Products: These include prescription solutions and gels primarily for the treatment and management of acute and chronic wounds, including diabetic foot ulcers and burns.
Animal Health Products: The company provides topical solutions and gels specifically designed for wound care and skin conditions in animals.

AI Analysis | Feedback

Sonoma Pharmaceuticals (SNOA)

Sonoma Pharmaceuticals primarily sells its products to other companies, which then distribute or sell the products to healthcare providers and, in some cases, directly to individuals. The company's major customers, as disclosed in its financial filings, are:

Cardinal Health (CAH)
McKesson Medical-Surgical (a subsidiary of McKesson Corporation - MCK)

AI Analysis | Feedback

MicroSafe Group
Smith & Nephew (SNN)
Te Arai BioFarma

AI Analysis | Feedback

Amy Trombly, Chief Executive Officer

Amy Trombly has two decades of experience counseling public companies in corporate and securities law, as well as mergers and acquisitions. She has owned and managed Trombly Business Law, PC since 2002. Earlier in her career, Ms. Trombly served as a Vice President at State Street Bank and as Special Counsel at the U.S. Securities and Exchange Commission.

Jerry Dvonch, Chief Financial Officer

Jerry Dvonch joined Sonoma Pharmaceuticals from SpineCenter Atlanta, where he was the controller and Senior Vice President of Finance and Accounting since March 2017. Previously, he was a consultant controller for DS Healthcare Group, Inc. from March 2016 to April 2016. From July 2005 to July 2015, he held positions as the director for external reporting and director of finance at NeoGenomics Laboratories. Mr. Dvonch is a licensed Certified Public Accountant in New York and possesses over 10 years of experience with SEC reporting.

Bruce Thornton, Chief Operating Officer

Bruce Thornton has served as Sonoma Pharmaceuticals' Chief Operating Officer, Vice President of Global Operations, and US General Manager since 2004. Prior to this, he was the Vice President of Operations for Jomed (formerly EndoSonic Corp.) from January 1999 to September 2003, and then Vice President of Manufacturing for Volcano Therapeutics following its acquisition of Jomed, until March 2004.

Jerry McLaughlin, Lead Independent Director

Jerry McLaughlin served as Interim Chief Executive Officer of Applied BioCode, Inc. from November 2011 to April 2013. Since April 2011, he has been the founder, Chairman, and Chief Executive Officer of DataStream Medical Imaging Systems, Inc. His past roles include President of DataFlow Information Systems from July 2007 to December 2011, and President and Chief Executive Officer of CompuMed, Inc. from May 2002 to June 2007.

Philippe Weigerstorfer, Independent Director

Philippe Weigerstorfer contributes extensive pharmaceutical and dermatology experience to Sonoma's board and has a history of expanding businesses internationally. He started his career in marketing at Sandoz and Novartis, moving into leadership roles for global business units in cardiovascular, dermatology, and other areas. In 1999, he joined Galencia Ltd's executive team, where he managed retail, pre-wholesale, business development, and M&A divisions.

AI Analysis | Feedback

Key Risks to Sonoma Pharmaceuticals (SNOA)

Sonoma Pharmaceuticals (SNOA) faces several significant risks to its business operations and financial stability. These can be broadly categorized as follows:

Financial Viability and Capital Needs: Sonoma Pharmaceuticals is currently unprofitable and its ability to generate sufficient revenue to cover its cash needs and fund ongoing development is a primary concern. The company's small market capitalization and past shareholder dilution further highlight the challenges related to its financial and corporate stability. The volatility of its stock price is also influenced by its ability to secure additional capital.
Regulatory and Clinical Development Risks: The company's business is highly dependent on regulatory and clinical developments. Risks include potential changes in regulatory guidelines, the possibility that scientific data may not meet regulatory standards, and the need to obtain required regulatory clearances or approvals for its products. There is also a risk that positive clinical results observed in trials may not be successfully replicated in real-world patient settings.
Market Competition and Product Penetration: Sonoma Pharmaceuticals operates in a competitive pharmaceutical industry. Key risks include the potential that the target market for its products may not be as large as anticipated, and challenges in effectively penetrating targeted markets. The success of its distribution partners in marketing and selling products also plays a crucial role and presents an operational risk.

AI Analysis | Feedback

null

AI Analysis | Feedback

Sonoma Pharmaceuticals (SNOA) develops and produces stabilized hypochlorous acid (HOCl) products using its patented Microcyn® Technology for a variety of applications, including wound care, dermatology, eye care, oral and nasal care, podiatry, animal health care, and non-toxic disinfectants. The addressable markets for their main products and services are as follows:

U.S. Skin Care Market: This market, which includes dermatology and cosmetics, is projected to reach nearly $40 billion by 2030.
Global Eye Care Market: The global eye care market size was estimated at $70.78 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.72% from 2024 to 2030.
U.S. Advanced Wound Care OTC Market: This market was estimated at $2.77 billion in 2024 and is projected to reach $6.61 billion by 2033, with a CAGR of 10.33% from 2025 to 2033.
Global Wound Irrigation Systems Market: This market was valued at approximately $318.7 million in 2024 and is predicted to grow to around $496.4 million by 2035, with a CAGR of 4.11% from 2025 to 2035.
Global Natural Skin Care Products Market: This market was valued at $6.7 billion in 2021 and is expected to expand at a CAGR of 6.6% from 2022 to 2030.
Global Animal Health Market: The global animal health market size was valued at $62.40 billion in 2023 and is projected to grow at a CAGR of 9.0% from 2024 to 2030.

AI Analysis | Feedback

Sonoma Pharmaceuticals (SNOA) is expected to drive future revenue growth over the next 2-3 years through several key strategies:

Launch of New Products: The company continues to invest in research and development, leading to the introduction of new products. Recent examples include Lumacyn™ Clarifying Mist for skincare (January 2024), expanded sizes for Microcyn® Negative Pressure Wound Therapy Solution products (April 2024), hypochlorous acid-based acne products launched in over 1,200 UK stores (April 2025), HOCl-based diaper rash products with Walmart (August 2025), and a new HOCl wound cleanser with Medline Industries (October 2025). These new offerings are anticipated to contribute significantly to revenue growth.
Expansion of Distribution Networks and Partnerships: Sonoma Pharmaceuticals is actively growing its distribution network and forging new partnerships. This includes expanding its MicrocynAH® animal health care products into additional retail chains like Menards® (May 2024), forming an agreement with NovaBay Pharmaceuticals for the sale and marketing of Avenova®-branded products in the European Union (January 2024), and broadening partnerships with major U.S. retailers for consumer-focused products (July 2025). The company has also added a new distributor in Ukraine.
International Market Expansion and Regulatory Approvals: Sonoma is focused on expanding its global footprint by aggressively pursuing worldwide regulatory approvals. Notable achievements include the successful transition of all commercialized European products to the new EU Medical Device Regulation (MDR) ahead of the 2028 deadline and registration of products with the MHRA in the United Kingdom (June 2025). Additionally, they received regulatory approval for wound care products in Ukraine (April 2025), contributing to increased European and Latin American sales.
Growth in Key Product Categories, particularly Dermatology and Wound Care: The company sees strong potential in specific therapeutic areas. U.S. sales have shown growth driven by consumer-focused animal health care and wound care products. Dermatology is highlighted as a high-margin area for growth, with efforts to position products for med spas and dermatologists, including office dispense lines. Wound care remains a stable and growing segment.
Increasing Demand for Microcyn® Technology: Underlying all these efforts is the sustained and growing worldwide demand for Sonoma's patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products across various applications. The CEO has explicitly stated "significant worldwide demand for our technology" as a driver.

AI Analysis | Feedback

Share Issuance

Sonoma Pharmaceuticals implemented a 1-for-20 reverse stock split effective August 29, 2024, reducing the number of outstanding common shares from approximately 20 million to about 1 million.
Concurrently with the reverse stock split, the company increased its authorized shares of common stock from 24,000,000 to 50,000,000.
The number of issued and outstanding shares increased from 1,634,265 on March 31, 2025, to 1,649,765 on September 30, 2025, and reached 1,701,076 as of November 3, 2025.

Capital Expenditures

Capital expenditures were reported at $106,000 in the first quarter of fiscal 2025.
These capital expenditures are considered calculated spending intended to facilitate growth.

Better Bets than Sonoma Pharmaceuticals (SNOA)

INDUSTRY: Pharmaceuticals

Higher Rev Chg 3Y Avg | Lower P/S (Values for SNOA: 11.2% | 0.4x)

SBFM (1373.8% | 0.2x)

Sunshine Biopharma

FLGC (47.5% | 0.1x)

Flora Growth

EGRX (15.1% | 0.0x)

Eagle Pharmaceuticals

Higher Rev Chg LTM (Value for SNOA: 25.0%)

AVDL (79.9%)

Avadel Pharmaceuticals

KNSA (56.2%)

Kiniksa Pharmaceuticals International

ANIP (48.9%)

ANI Pharmaceuticals

HROW (47.8%)

Harrow

LLY (36.8%)

Eli Lilly

Higher Rev Chg 3Y Avg (Value for SNOA: 11.2%)

ACAD (27.8%)

ACADIA Pharmaceuticals

CORT (23.6%)

Corcept Therapeutics

LLY (23.4%)

Eli Lilly

INDV (12.1%)

Indivior

ALKS (12.1%)

Alkermes

Higher Op Mgn LTM (Value for SNOA: -18.4%)

LLY (43.0%)

Eli Lilly

MRK (34.9%)

Merck

JNJ (26.2%)

Johnson & Johnson

PFE (24.6%)

Pfizer

BMY (23.8%)

Bristol-Myers Squibb

Higher CFO/Rev LTM (Value for SNOA: -12.9%)

BMY (34.6%)

Bristol-Myers Squibb

MRK (26.6%)

Merck

JNJ (26.3%)

Johnson & Johnson

PFE (20.8%)

Pfizer

LLY (20.5%)

Eli Lilly

Higher FCF/Rev LTM (Value for SNOA: -13.8%)

BMY (31.9%)

Bristol-Myers Squibb

MRK (20.3%)

Merck

JNJ (20.3%)

Johnson & Johnson

PFE (16.5%)

Pfizer

LLY (-0.1%)

Eli Lilly

Higher Total Yield (Value for SNOA: -58.5%)

PFE (13.7%)

Pfizer

MRK (10.2%)

Merck

BMY (9.9%)

Bristol-Myers Squibb

JNJ (7.5%)

Johnson & Johnson

LLY (1.9%)

Eli Lilly

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for SNOA: 11.2% | 0.4x)

MCK (12.6% | 0.3x)

McKesson

CI (13.6% | 0.3x)

Cigna

HUM (11.4% | 0.2x)

Humana

MOH (12.8% | 0.2x)

Molina Healthcare

OSCR (46.4% | 0.3x)

Oscar Health

Higher Rev Chg LTM (Value for SNOA: 25.0%)

ALNY (53.2%)

Alnylam Pharmaceuticals

NTRA (38.2%)

Natera

LLY (36.8%)

Eli Lilly

INSM (30.3%)

Insmed

PODD (27.1%)

Insulet

Higher Rev Chg 3Y Avg (Value for SNOA: 11.2%)

LLY (23.4%)

Eli Lilly

ISRG (16.3%)

Intuitive Surgical

BSX (15.6%)

Boston Scientific

UNH (11.4%)

UnitedHealth

AMGN (11.2%)

Amgen

Higher Op Mgn LTM (Value for SNOA: -18.4%)

LLY (43.0%)

Eli Lilly

MRK (34.9%)

Merck

JNJ (26.2%)

Johnson & Johnson

ABBV (24.1%)

AbbVie

UNH (6.1%)

UnitedHealth

Higher CFO/Rev LTM (Value for SNOA: -12.9%)

ABBV (35.0%)

AbbVie

MRK (26.6%)

Merck

JNJ (26.3%)

Johnson & Johnson

LLY (20.5%)

Eli Lilly

UNH (4.8%)

UnitedHealth

Higher FCF/Rev LTM (Value for SNOA: -13.8%)

ABBV (33.0%)

AbbVie

MRK (20.3%)

Merck

JNJ (20.3%)

Johnson & Johnson

UNH (4.0%)

UnitedHealth

LLY (-0.1%)

Eli Lilly

Higher Total Yield (Value for SNOA: -58.5%)

MRK (10.2%)

Merck

UNH (8.5%)

UnitedHealth

JNJ (7.5%)

Johnson & Johnson

ABBV (3.4%)

AbbVie

LLY (1.9%)

Eli Lilly

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for SNOA: 11.2% | 0.4x)

GPI (13.0% | 0.2x)

Group 1 Automotive

SNEX (29.6% | 0.0x)

StoneX

STNE (21.3% | 0.3x)

StoneCo

CNXC (17.9% | 0.3x)

Concentrix

GOLD (14.5% | 0.1x)

Gold.com

Higher Rev Chg LTM (Value for SNOA: 25.0%)

APP (86.4%)

AppLovin

NVDA (65.2%)

NVIDIA

PLTR (47.2%)

Palantir Technologies

MU (45.4%)

Micron Technology

AMD (31.8%)

Advanced Micro Devices

Higher Rev Chg 3Y Avg (Value for SNOA: 11.2%)

NVDA (91.6%)

NVIDIA

AVGO (25.2%)

Broadcom

META (17.3%)

Meta Platforms

MSFT (13.2%)

Microsoft

AMZN (11.3%)

Amazon.com

Higher Op Mgn LTM (Value for SNOA: -18.4%)

NVDA (58.8%)

NVIDIA

MSFT (46.3%)

Microsoft

GOOGL (32.2%)

Alphabet

AAPL (31.9%)

Apple

AMZN (11.4%)

Amazon.com

Higher CFO/Rev LTM (Value for SNOA: -12.9%)

MSFT (50.0%)

Microsoft

NVDA (44.4%)

NVIDIA

GOOGL (39.3%)

Alphabet

AAPL (26.6%)

Apple

AMZN (18.1%)

Amazon.com

Higher FCF/Rev LTM (Value for SNOA: -13.8%)

NVDA (41.3%)

NVIDIA

MSFT (26.6%)

Microsoft

AAPL (23.5%)

Apple

GOOGL (19.1%)

Alphabet

AMZN (2.0%)

Amazon.com

Higher Total Yield (Value for SNOA: -58.5%)

MSFT (3.6%)

Microsoft

GOOGL (3.5%)

Alphabet

AMZN (2.9%)

Amazon.com

AAPL (2.8%)

Apple

NVDA (2.2%)

NVIDIA

		Best Bets In Health Care Sector
	SNOA	RPRX	HALO	DOCS	CPRX	HRMY	LGND	ISRG	GMED	MD	HIMS
What You Pay
P/E	-1.7	22.1	13.6	32.4	13.7	11.8	78.9	75.0	28.1	11.4	58.0
P/EBIT	-1.9	10.7	10.6	33.2	11.5	8.9	57.4	73.2	27.4	7.7	67.5
What You Get
Rev Chg Q	56.6%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	25.0%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	11.2%	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	-20.7%	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Sonoma Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain?	Return

	Title
0	ARTICLES

Trade Ideas

Select ideas related to SNOA. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.4%	21.4%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.4%	-7.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	18.0%	18.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.9%	3.9%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	12.2%	12.2%	-5.1%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ZETA	Zeta Global	4.6	8.3%	15.1%
SGML	Sigma Lithium	1.6	7.3%	29.2%
USAS	Americas Gold And Silver	1.6	6.6%	557.6%
CPNG	Coupang	44.2	6.4%	10.4%
LION	Lionsgate Studios	2.7	4.6%	-69.9%
BBW	Build-A-Bear Workshop	0.8	4.4%	37.8%
XRAY	Dentsply Sirona	2.3	4.2%	-36.3%
BLMN	Bloomin Brands	0.6	3.8%	-41.2%
FUN	Six Flags Entertainment	1.5	3.8%	-69.1%
SVM	Silvercorp Metals	1.9	3.6%	198.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FLY	Firefly Aerospace	3.3	-13.7%	-61.3%
TMC	TMC The Metals	2.5	-10.5%	508.9%
ORGO	Organogenesis	0.7	-10.1%	64.8%
AAOI	Applied Optoelectronics	2.4	-9.3%	0.8%
BKSY	BlackSky Technology	0.7	-9.0%	79.0%
LUNR	Intuitive Machines	1.8	-8.7%	-16.0%
RCAT	Red Cat	0.8	-8.7%	-35.4%
RGTI	Rigetti Computing	6.7	-8.7%	46.7%
RDW	Redwire	1.0	-8.6%	-56.6%
RKLB	Rocket Lab	36.4	-8.5%	177.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	0.9	71.5%	59.0%
RZLT	Rezolute	0.3	44.3%	-45.5%
DVAX	Dynavax Technologies	1.8	41.5%	20.4%
LUNR	Intuitive Machines	1.8	40.6%	-16.0%
UAMY	United States Antimony	0.7	39.0%	252.5%
FOLD	Amicus Therapeutics	4.4	30.9%	51.3%
ADEA	Adeia	1.9	30.3%	23.0%
HUT	Hut 8	5.2	28.6%	142.3%
AAOI	Applied Optoelectronics	2.4	27.1%	0.8%
SGML	Sigma Lithium	1.6	24.9%	29.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TPL	Texas Pacific Land	6.6	-67.9%	-21.5%
LW	Lamb Weston	5.9	-29.0%	-35.3%
TLRY	Tilray Brands	10.2	-22.2%	-27.8%
TDUP	ThredUp	0.8	-18.2%	348.2%
LAB	Standard BioTools	0.5	-16.9%	-21.1%
OLMA	Olema Pharmaceuticals	2.2	-14.9%	349.9%
EVEX	Eve	1.4	-12.0%	-21.9%
IRON	Disc Medicine	2.8	-11.2%	26.7%
AVO	Mission Produce	0.8	-11.1%	-18.8%
CABO	Cable One	0.7	-10.6%	-67.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TLRY	Tilray Brands	10.2	876.4%	-27.8%
HPP	Hudson Pacific Properties	4.7	452.7%	-51.0%
WVE	WAVE Life Sciences	2.9	139.2%	43.7%
TE	T1 Energy	1.1	106.7%	400.0%
VERA	Vera Therapeutics	3.4	82.1%	26.7%
OMER	Omeros	0.9	66.2%	59.0%
RKLB	Rocket Lab	36.4	65.8%	177.4%
PL	Planet Labs PBC	5.9	65.0%	379.2%
AAOI	Applied Optoelectronics	2.4	63.5%	0.8%
LUNR	Intuitive Machines	1.8	62.4%	-16.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-72.0%	-45.5%
JANX	Janux Therapeutics	0.9	-59.0%	-73.4%
FRMI	Fermi	5.3	-46.0%	-76.6%
LENZ	LENZ Therapeutics	0.5	-43.5%	-41.6%
GOGO	Gogo	0.6	-35.3%	-43.0%
HPK	HighPeak Energy	0.5	-33.9%	-70.4%
PACB	Pacific Biosciences of California	0.5	-32.7%	-3.3%
LDI	loanDepot	0.4	-29.6%	3.9%
ORIC	ORIC Pharmaceuticals	0.6	-29.0%	2.2%
LW	Lamb Weston	5.9	-28.6%	-35.3%

Peer Comparisons for Sonoma Pharmaceuticals

Peers to compare with:

Financials

	SNOA	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Sonoma P.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Price	3.61	23.26	24.49	305.09	78.16	273.40	51.32
Mkt Cap	0.0	21.9	32.6	284.9	309.2	4,074.4	158.8
Rev LTM	17	55,295	34,296	65,402	57,696	408,625	56,496
Op Inc LTM	-3	3,624	1,644	11,544	12,991	130,214	7,584
FCF LTM	-2	2,800	627	11,854	12,733	96,184	7,327
FCF 3Y Avg	-3	2,978	1,400	11,753	13,879	100,503	7,366
CFO LTM	-2	3,697	2,919	13,483	13,744	108,565	8,590
CFO 3Y Avg	-3	3,672	3,896	13,498	14,736	111,559	8,697

Growth & Margins

	SNOA	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Sonoma P.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Rev Chg LTM	25.0%	3.2%	13.8%	4.5%	8.9%	6.0%	7.4%
Rev Chg 3Y Avg	11.2%	-3.9%	6.5%	2.6%	3.7%	1.8%	3.2%
Rev Chg Q	56.6%	4.2%	14.4%	9.1%	7.5%	9.6%	9.4%
QoQ Delta Rev Chg LTM	13.6%	1.1%	3.7%	2.1%	1.8%	2.1%	2.1%
Op Mgn LTM	-18.4%	6.6%	4.8%	17.7%	22.5%	31.9%	12.1%
Op Mgn 3Y Avg	-31.6%	7.4%	7.2%	16.4%	24.2%	30.8%	11.9%
QoQ Delta Op Mgn LTM	5.9%	-0.2%	-1.4%	0.6%	0.4%	0.1%	0.2%
CFO/Rev LTM	-12.9%	6.7%	8.5%	20.6%	23.8%	26.6%	14.6%
CFO/Rev 3Y Avg	-19.7%	6.8%	12.7%	21.4%	26.1%	28.4%	17.1%
FCF/Rev LTM	-13.8%	5.1%	1.8%	18.1%	22.1%	23.5%	11.6%
FCF/Rev 3Y Avg	-20.7%	5.5%	4.6%	18.6%	24.6%	25.6%	12.1%

Valuation

	SNOA	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Sonoma P.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Cap	0.0	21.9	32.6	284.9	309.2	4,074.4	158.8
P/S	0.4	0.4	1.0	4.4	5.4	10.0	2.7
P/EBIT	-1.9	6.8	19.9	25.1	22.5	31.3	21.2
P/E	-1.7	8.6	572.7	36.0	29.9	41.0	33.0
P/CFO	-2.7	5.9	11.2	21.1	22.5	37.5	16.2
Total Yield	-58.5%	14.1%	2.3%	5.0%	5.4%	2.8%	3.9%
Dividend Yield	0.0%	2.5%	2.1%	2.2%	2.1%	0.4%	2.1%
FCF Yield 3Y Avg	-65.9%	10.6%	5.5%	6.4%	6.0%	3.1%	5.7%
D/E	0.1	0.5	0.7	0.2	0.1	0.0	0.2
Net D/E	-0.4	0.3	0.6	0.2	0.0	0.0	0.1

Returns

	SNOA	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Sonoma P.	HP	Hewlett .	Internat.	Cisco Sy.	Apple
1M Rtn	11.4%	-1.8%	14.4%	0.6%	2.7%	-1.5%	1.7%
3M Rtn	-10.6%	-11.9%	2.7%	7.9%	17.0%	7.1%	4.9%
6M Rtn	25.8%	-4.0%	34.5%	6.6%	15.2%	36.3%	20.5%
12M Rtn	31.3%	-27.0%	16.2%	40.5%	34.5%	7.5%	23.7%
3Y Rtn	-82.1%	-1.9%	71.1%	143.1%	81.3%	120.2%	76.2%
1M Excs Rtn	8.0%	-5.6%	12.9%	-2.2%	-0.0%	-3.7%	-1.1%
3M Excs Rtn	-15.0%	-16.2%	-1.7%	3.6%	12.7%	2.8%	0.6%
6M Excs Rtn	13.5%	-16.3%	22.3%	-5.7%	3.0%	24.0%	8.2%
12M Excs Rtn	18.7%	-42.9%	-0.7%	25.0%	19.9%	-8.4%	9.0%
3Y Excs Rtn	-166.1%	-83.5%	-11.2%	59.6%	-1.2%	28.4%	-6.2%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 3/31	LTM	2025	2024	2023	2022	2021	2020
Period End	9/30/2025	3/31/2025	3/31/2024	3/31/2023	3/31/2022	3/31/2021	3/31/2020
Filing Date	11/4/2025	6/17/2025	6/17/2024	6/21/2023	7/13/2022	7/14/2021	7/10/2020
Key Financials
Total Revenue	17	14	13	13	13	19	18
EBITDA	-3	-4	-5	-4	-6	-3	-3
Operating Income	-3	-4	-5	-5	-6	-3	-7
Net Income	-3	-3	-5	-5	-5	-4	-3
EPS	-2.10	-2.79	-10.63	-30.40	-38.40	-39.40	-44.80
Growth Rates
Total Revenue Growth	25.0%	12.2%	-4.0%	5.1%	-32.2%	3.9%	-5.5%
EBITDA Growth	27.5%	21.1%	-1.8%	22.0%	-76.9%	-0.2%	70.4%
Operating Income Growth	27.1%	21.1%	-2.9%	22.4%	-70.7%	53.3%	34.4%
Net Income Growth	5.6%	28.5%	6.1%	-1.3%	-28.8%	-19.4%	72.0%
Margins
EBITDA Margin	-17.6%	-25.0%	-35.5%	-33.5%	-45.1%	-17.3%	-17.9%
Operating Income Margin	-18.4%	-26.0%	-36.9%	-34.4%	-46.6%	-18.5%	-41.2%
Net Income Margin	-20.5%	-24.2%	-38.0%	-38.8%	-40.3%	-21.2%	-18.5%
Cash & Debt
Total Cash	3	5	3	4	7	4	4
Total Debt	1	0	1	1	1	3	1
Net Debt / (Cash)	-2	-5	-3	-3	-6	-2	-3
Cash Flows
Net Cash from Operations	-2	-0	-2	-6	-4	-3	-5
Free Cash from Operations	-2	-0	-2	-6	-4	-4	-5
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	0	-0	-0	-0	-0	-0

$ Mil \| FY: 3/31	2026Q2	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/4/2025	8/7/2025	6/17/2025	2/5/2025	11/7/2024	8/8/2024	6/17/2024	2/8/2024	11/13/2023	8/10/2023	6/21/2023	2/14/2023
Key Financials Quarterly
Total Revenue	6	4	4	4	4	3	3	3	3	3	3	3
Ebitda	-0	-1	-1	-1	-1	-1	-1	-1	-1	-1	-1	-2
Operating Income	-0	-1	-1	-1	-1	-1	-1	-1	-1	-1	-1	-2
Net Income	-1	-1	-1	-1	-1	-1	-1	-1	-1	-1	-1	-2
EPS	-0.32	-0.76	-0.39	-0.63	-0.59	-1.34	-1.37	-1.59	-5.75	-5.80	-5.60	-12.40
Key Financials TTM
Total Revenue TTM	17	15	14	14	14	13	13	12	12	13	13	13
Ebitda TTM	-3	-3	-4	-4	-4	-4	-5	-4	-5	-5	-4	-6
Operating Income TTM	-3	-4	-4	-4	-4	-5	-5	-4	-5	-5	-5	-6
Net Income TTM	-3	-4	-3	-4	-4	-5	-5	-5	-6	-6	-5	-7
Growth Rates Quarterly
Total Revenue Growth	56.6%	18.4%	9.2%	13.6%	31.1%	-1.1%	14.1%	6.6%	-18.0%	-14.0%	31.2%	1.4%
EBITDA Growth	63.1%	6.6%	54.3%	-24.9%	29.9%	5.1%	-22.9%	55.7%	-65.4%	-45.0%	63.0%	-95.7%
Operating Income Growth	60.4%	6.6%	53.4%	-22.2%	29.6%	5.4%	-22.8%	54.0%	-65.3%	-45.0%	62.5%	-91.4%
Net Income Growth	12.5%	-8.6%	27.3%	-7.2%	58.9%	19.4%	18.4%	55.3%	-45.9%	-59.9%	55.6%	-105.4%
Margins Quarterly
EBITDA Margin	-5.4%	-26.4%	-16.6%	-28.0%	-22.8%	-33.4%	-39.8%	-25.5%	-42.6%	-34.9%	-36.9%	-61.2%
Operating Income Margin	-6.0%	-27.3%	-17.5%	-28.9%	-23.7%	-34.6%	-41.0%	-26.9%	-44.2%	-36.2%	-38.1%	-62.3%
Net Income Margin	-9.5%	-30.9%	-20.7%	-26.0%	-17.0%	-33.7%	-31.0%	-27.6%	-54.3%	-41.4%	-43.4%	-65.9%
Cash & Debt
Total Cash	3	4	5	5	4	3	3	2	2	4	4	3
Total Debt	1	1	0	0	0	0	1	0	1	1	1	0
Net Debt / (Cash)	-2	-3	-5	-5	-4	-2	-3	-2	-2	-3	-3	-2
Cash Flows Quarterly
FCF from Operations	-1	-2	-0	1	0	-1	0	-1	-1	-0	-2	-0
Cash Flows TTM
FCF from Operations TTM	-2	-1	-0	0	-2	-3	-2	-5	-4	-5	-6	-5
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-0.5%	-2.2%	-1.3%	-2.1%	-1.7%	-2.4%	-2.2%	-1.6%	-2.5%	-2.5%	-2.1%	-3.8%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-1.6%	-1.8%	-1.9%	-2.3%	-2.1%	-2.3%	-2.3%	-2.2%	-2.8%	-2.5%	-2.3%	-3.3%

Segment Financials

null

Price Behavior

Price Behavior

Market Price	$3.61
Market Cap ($ Bil)	0.0
First Trading Date	12/06/2016
Distance from 52W High	-32.5%
	50 Days	200 Days
DMA Price	$3.60	$3.53
DMA Trend	up	down
Distance from DMA	0.2%	2.2%
	3M	1YR
Volatility	58.8%	131.9%
Downside Capture	142.11	160.96
Upside Capture	59.29	163.55
Correlation (SPY)	25.0%	17.6%

SNOA Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.54	1.29	0.98	0.82	1.18	1.09
Up Beta	0.53	0.82	0.86	-2.98	1.37	0.69
Down Beta	0.54	2.55	1.97	1.18	0.32	1.12
Up Capture	-83%	20%	-31%	134%	203%	46%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	6	15	20	40	92	292
Down Capture	137%	139%	132%	187%	126%	110%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	13	24	40	78	145	434

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of SNOA With Other Asset Classes (Last 1Y)
	SNOA	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	37.3%	15.1%	17.8%	72.1%	8.6%	4.4%	-8.2%
Annualized Volatility	130.8%	17.2%	19.4%	19.3%	15.2%	17.0%	35.0%
Sharpe Ratio	0.73	0.65	0.72	2.70	0.34	0.09	-0.08
Correlation With Other Assets		11.1%	17.6%	-11.0%	3.1%	6.8%	8.6%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of SNOA With Other Asset Classes (Last 5Y)
	SNOA	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-52.7%	8.4%	14.7%	18.7%	11.5%	4.6%	30.8%
Annualized Volatility	118.4%	14.5%	17.1%	15.5%	18.7%	18.9%	48.6%
Sharpe Ratio	-0.12	0.40	0.70	0.97	0.50	0.16	0.57
Correlation With Other Assets		12.5%	15.2%	0.7%	7.0%	9.8%	8.5%

Based On 10-Year Data

		Comparison of SNOA With Other Asset Classes (Last 10Y)
	SNOA	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-45.5%	9.9%	14.8%	15.3%	7.0%	5.3%	69.2%
Annualized Volatility	106.5%	16.6%	18.0%	14.7%	17.6%	20.8%	55.8%
Sharpe Ratio	-0.11	0.49	0.71	0.86	0.32	0.22	0.90
Correlation With Other Assets		9.3%	11.9%	3.8%	8.4%	6.4%	5.4%

Short Interest

Short Interest: As Of Date	12152025
Short Interest: Shares Quantity	15,480
Short Interest: % Change Since 11302025	18.3%
Average Daily Volume	27,616
Days-to-Cover Short Interest	1
Basic Shares Quantity	1,646,000
Short % of Basic Shares	0.9%

Returns Analyses

	Title
0	Sonoma Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/8/2018	-11.1%	-8.0%	-40.2%
6/13/2018	-21.2%	-34.4%	-38.2%
2/7/2018	-4.0%	-3.5%	-12.8%
11/9/2017	-5.1%	6.4%	-0.6%
6/5/2017	-7.4%	-9.0%	-11.4%
2/9/2017	10.3%	1.4%	11.7%
11/10/2016			�
6/16/2016
...
SUMMARY STATS
# Positive	1	2	2
# Negative	16	15	15
Median Positive	10.3%	3.9%	11.7%
Median Negative	-7.4%	-8.5%	-12.8%
Max Positive	10.3%	6.4%	11.7%
Max Negative	-21.2%	-34.4%	-40.2%

	Forward Returns
11/8/2018	-11.1%	-8.0%	-40.2%
6/13/2018	-21.2%	-34.4%	-38.2%
2/7/2018	-4.0%	-3.5%	-12.8%
11/9/2017	-5.1%	6.4%	-0.6%
6/5/2017	-7.4%	-9.0%	-11.4%
2/9/2017	10.3%	1.4%	11.7%
11/10/2016			�
6/16/2016
2/4/2016
11/5/2015
6/11/2015
11/13/2014
6/12/2014
2/13/2014
11/19/2013
6/13/2013
2/13/2013
SUMMARY STATS
# Positive	1	2	2
# Negative	16	15	15
Median Positive	10.3%	3.9%	11.7%
Median Negative	-7.4%	-8.5%	-12.8%
Max Positive	10.3%	6.4%	11.7%
Max Negative	-21.2%	-34.4%	-40.2%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11042025	10-Q 9/30/2025
6302025	8072025	10-Q 6/30/2025
3312025	6172025	10-K 3/31/2025
12312024	2052025	10-Q 12/31/2024
9302024	11072024	10-Q 9/30/2024
6302024	8082024	10-Q 6/30/2024
3312024	6172024	10-K 3/31/2024
12312023	2082024	10-Q 12/31/2023
9302023	11132023	10-Q 9/30/2023
6302023	8102023	10-Q 6/30/2023
3312023	6212023	10-K 3/31/2023
12312022	2142023	10-Q 12/31/2022
9302022	11142022	10-Q 9/30/2022
6302022	8112022	10-Q 6/30/2022
3312022	7132022	10-K 3/31/2022
12312021	2112022	10-Q 12/31/2021

Insider Activity

Expand for Morenull

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Sonoma Pharmaceuticals (SNOA)

Market Price (12/28/2025): $3.58 | Market Cap: $5.9 MilSector: Health Care | Industry: Pharmaceuticals

Sonoma Pharmaceuticals (SNOA)

Market Price (12/28/2025): $3.58Market Cap: $5.9 MilSector: Health CareIndustry: Pharmaceuticals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

SNOA Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Sonoma Pharmaceuticals (SNOA)

Sonoma Pharmaceuticals (SNOA)

Key Risks to Sonoma Pharmaceuticals (SNOA)

Interactive Breakdown

Better Bets than Sonoma Pharmaceuticals (SNOA)

INDUSTRY: Pharmaceuticals

Higher Rev Chg 3Y Avg | Lower P/S (Values for SNOA: 11.2% | 0.4x)

Higher Rev Chg LTM (Value for SNOA: 25.0%)

Higher Rev Chg 3Y Avg (Value for SNOA: 11.2%)

Higher Op Mgn LTM (Value for SNOA: -18.4%)

Higher CFO/Rev LTM (Value for SNOA: -12.9%)

Higher FCF/Rev LTM (Value for SNOA: -13.8%)

Higher Total Yield (Value for SNOA: -58.5%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for SNOA: 11.2% | 0.4x)

Higher Rev Chg LTM (Value for SNOA: 25.0%)

Higher Rev Chg 3Y Avg (Value for SNOA: 11.2%)

Higher Op Mgn LTM (Value for SNOA: -18.4%)

Higher CFO/Rev LTM (Value for SNOA: -12.9%)

Higher FCF/Rev LTM (Value for SNOA: -13.8%)

Higher Total Yield (Value for SNOA: -58.5%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for SNOA: 11.2% | 0.4x)

Higher Rev Chg LTM (Value for SNOA: 25.0%)

Higher Rev Chg 3Y Avg (Value for SNOA: 11.2%)

Higher Op Mgn LTM (Value for SNOA: -18.4%)

Higher CFO/Rev LTM (Value for SNOA: -12.9%)

Higher FCF/Rev LTM (Value for SNOA: -13.8%)

Higher Total Yield (Value for SNOA: -58.5%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Sonoma Pharmaceuticals

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Market Price (12/28/2025): $3.58 | Market Cap: $5.9 Mil
Sector: Health Care | Industry: Pharmaceuticals

Market Price (12/28/2025): $3.58
Market Cap: $5.9 Mil
Sector: Health Care
Industry: Pharmaceuticals